Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
about
Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development.A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy.An Overview on the Clinical Development of Tau-Based Therapeutics.The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.
P2860
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Potential of Low Dose Leuco-Methylthioninium Bis
@nl
Potential of Low Dose Leuco-Me ...... in a Phase III Clinical Trial.
@en
type
label
Potential of Low Dose Leuco-Methylthioninium Bis
@nl
Potential of Low Dose Leuco-Me ...... in a Phase III Clinical Trial.
@en
prefLabel
Potential of Low Dose Leuco-Methylthioninium Bis
@nl
Potential of Low Dose Leuco-Me ...... in a Phase III Clinical Trial.
@en
P2093
P2860
P50
P356
P1476
Potential of Low Dose Leuco-Me ...... in a Phase III Clinical Trial
@en
P2093
Bjoern O Schelter
Charles S Davis
Claude M Wischik
Damon J Wischik
Gernot Riedel
Giovanni B Frisoni
Gordon K Wilcock
Hans J Moebius
Jiri H Hardlund
John M D Storey
P2860
P304
P356
10.3233/JAD-170560
P577
2018-01-01T00:00:00Z